Paper40155893
Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review.
Pangprasertkul S and 4 others. BMC Infect Dis, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review. Papers, record 40155893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40155893
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Isoniazid | Major topic |
| Antitubercular Agents | Major topic |
| Rifampin | Major topic |
| Latent Tuberculosis | Major topic |
| Tuberculosis | Major topic |
| Humans | |
| Child | |
| Adolescent | |
| Child, Preschool | |
| Infant | |
| Drug Administration Schedule | |
| Male | |
| Young Adult | |
| Female |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07811518 | Latent Infection Freshmen Tracking for Tuberculosis | Background |
Source ClinicalTrials.gov
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28763500 | Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. | PLoS One | 2017 | https://conductscience.org/library/papers/28763500 | PubMed |
| 2 | 22717944 | Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. | Thorax | 2013 | https://conductscience.org/library/papers/22717944 | PubMed |
| 3 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 4 | 33969644 | Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review. | Pediatr Pulmonol | 2021 | https://conductscience.org/library/papers/33969644 | PubMed |
| 5 | 35868608 | Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection. | Int J Infect Dis | 2022 | https://conductscience.org/library/papers/35868608 | PubMed |
| 6 | 36815322 | Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/36815322 | PubMed |
| 7 | 32199484 | The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. | Lancet | 2020 | https://conductscience.org/library/papers/32199484 | PubMed |
| 8 | 28734517 | Tuberculosis in Children. | Pediatr Clin North Am | 2017 | https://conductscience.org/library/papers/28734517 | PubMed |
| 9 | 30029896 | Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. | Tuberculosis (Edinb) | 2018 | https://conductscience.org/library/papers/30029896 | PubMed |
| 10 | 27088582 | Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection. | Pediatr Infect Dis J | 2016 | https://conductscience.org/library/papers/27088582 | PubMed |
| 11 | 37083926 | Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/37083926 | PubMed |
| 12 | 34747900 | Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. | J Chin Med Assoc | 2021 | https://conductscience.org/library/papers/34747900 | PubMed |
| 13 | 39301128 | 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients. | IJTLD Open | 2024 | https://conductscience.org/library/papers/39301128 | PubMed |
| 14 | 28003956 | Global Burden of Childhood Tuberculosis. | Pneumonia (Nathan) | 2016 | https://conductscience.org/library/papers/28003956 | PubMed |
| 15 | 33215187 | Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33215187 | PubMed |
| 16 | 32703775 | Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children. | Eur Respir J | 2021 | https://conductscience.org/library/papers/32703775 | PubMed |
| 17 | 25658592 | Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa. | PLoS One | 2015 | https://conductscience.org/library/papers/25658592 | PubMed |
| 18 | 27780211 | The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. | PLoS Med | 2016 | https://conductscience.org/library/papers/27780211 | PubMed |
| 19 | 29910114 | Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. | Am J Prev Med | 2018 | https://conductscience.org/library/papers/29910114 | PubMed |
| 20 | 28575208 | High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. | Clin Infect Dis | 2017 | https://conductscience.org/library/papers/28575208 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42952506 | Factors associated with acceptance of preventive treatment among older adults with latent tuberculosis infection in Huzhou, Zhejiang province: a cross-sectional study. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42952506 | PubMed |
| 42912081 | Safety of tuberculosis-preventive treatment in children aged under 5 years: A rapid review. | Rev Soc Bras Med Trop | 2026 | https://conductscience.org/library/papers/42912081 | PubMed |
| 42758766 | Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above - Lessons from a tuberculosis preventive therapy surge activity in Zambia. | PLOS Glob Public Health | 2026 | https://conductscience.org/library/papers/42758766 | PubMed |
| 42237122 | Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42237122 | PubMed |
| 41650118 | Combination interventions to control the tuberculosis epidemic in the Karamoja subregion of Uganda: A modelling analysis. | PLOS Glob Public Health | 2026 | https://conductscience.org/library/papers/41650118 | PubMed |
| 41354746 | Acceptance of preventive therapy for latent tuberculosis infection in Chinese children and adolescents: a systematic review and meta-analysis. | Sci Rep | 2025 | https://conductscience.org/library/papers/41354746 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40155893
GET https://conductscience.org/api/papers/v1/40155893/references?page=2